156 related articles for article (PubMed ID: 21502616)
1. Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model.
Zelenitsky S; Alkurdi N; Weber Z; Ariano R; Zhanel G
Antimicrob Agents Chemother; 2011 Jul; 55(7):3627-30. PubMed ID: 21502616
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
MacGowan AP; Noel AR; Tomaselli S; Elliott HC; Bowker KE
Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
[TBL] [Abstract][Full Text] [Related]
4. Reduced susceptibility to vancomycin in methicillin resistant staphylococcus aureus: a time for action.
Amatya R; Devkota P; Gautam A
Nepal Med Coll J; 2014 Sep; 16(1):42-4. PubMed ID: 25799810
[TBL] [Abstract][Full Text] [Related]
5. Nemonoxacin Enhances Antibacterial Activity and Anti-Resistance Mutation Ability of Vancomycin against Methicillin-Resistant Staphylococcus aureus in an
Huang J; Guo S; Li X; Yuan F; Li Y; Xu B; Gu J; Qiao Y
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0180021. PubMed ID: 34902266
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia.
Harigaya Y; Bulitta JB; Forrest A; Sakoulas G; Lesse AJ; Mylotte JM; Tsuji BT
Antimicrob Agents Chemother; 2009 Sep; 53(9):3894-901. PubMed ID: 19596879
[TBL] [Abstract][Full Text] [Related]
7. Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus.
Singh NB; Yim J; Jahanbakhsh S; Sakoulas G; Rybak MJ
Diagn Microbiol Infect Dis; 2018 Aug; 91(4):363-370. PubMed ID: 29807674
[TBL] [Abstract][Full Text] [Related]
8. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
[TBL] [Abstract][Full Text] [Related]
9. Growing Resistance to Vancomycin among Methicillin Resistant Staphylococcus Aureus Isolates from Different Clinical Samples.
Pahadi PC; Shrestha UT; Adhikari N; Shah PK; Amatya R
JNMA J Nepal Med Assoc; 2014; 52(196):977-81. PubMed ID: 26982895
[TBL] [Abstract][Full Text] [Related]
10. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
Mirza HC; Sancak B; Gür D
Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
[TBL] [Abstract][Full Text] [Related]
11. [Investigation of antibiotic resistance patterns and reduced vancomycin susceptibilities of methicillin-resistant Staphylococcus aureus isolates: a multi-center study].
Çıkman A; Aydın M; Gülhan B; Parlak M; Gültepe B; Kalaycı Y; Bayındır Bilmen F; Solmaz S; Özekinci T
Mikrobiyol Bul; 2015 Apr; 49(2):240-8. PubMed ID: 26167824
[TBL] [Abstract][Full Text] [Related]
12. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
13. Emergence of vancomycin-intermediate and -resistant Staphylococcus aureus among methicillin-resistant S. aureus isolated from clinical specimens in the northwest of Iran.
Ghahremani M; Jazani NH; Sharifi Y
J Glob Antimicrob Resist; 2018 Sep; 14():4-9. PubMed ID: 29454049
[TBL] [Abstract][Full Text] [Related]
14. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
Kebriaei R; Rice SA; Stamper KC; Rybak MJ
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
[TBL] [Abstract][Full Text] [Related]
15. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus.
Hagihara M; Wiskirchen DE; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2012 Jan; 56(1):202-7. PubMed ID: 22006007
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.
Vidaillac C; Leonard SN; Rybak MJ
Antimicrob Agents Chemother; 2009 Nov; 53(11):4712-7. PubMed ID: 19738009
[TBL] [Abstract][Full Text] [Related]
17. Trend in vancomycin susceptibility and correlation with molecular characteristics of methicillin-resistant Staphylococcus aureus causing invasive infections in Taiwan: results from the Tigecycline in vitro Surveillance in Taiwan (TIST) study, 2006-2010.
Tsao SM; Wang WY; Ko WC; Huang CH; Lu CT; Chuang YC; Liu CY; Liao CH; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Liu JW; Sun W; Wang LS; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Chen YH; Lu PL; Thomas CY; Hsueh PR
Diagn Microbiol Infect Dis; 2014 Oct; 80(2):162-7. PubMed ID: 25053202
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates.
Pitz AM; Yu F; Hermsen ED; Rupp ME; Fey PD; Olsen KM
J Clin Microbiol; 2011 Jan; 49(1):269-74. PubMed ID: 20962147
[TBL] [Abstract][Full Text] [Related]
19. Methicillin-resistant Staphylococcus aureus bacteremia in hemodialysis and nondialysis patients.
Kan LP; Lin JC; Chiu SK; Yeh YC; Lin TY; Yang YS; Wang YC; Wang NC; Yeh KM; Chang FY
J Microbiol Immunol Infect; 2014 Feb; 47(1):15-22. PubMed ID: 23040238
[TBL] [Abstract][Full Text] [Related]
20. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia.
Yeh YC; Yeh KM; Lin TY; Chiu SK; Yang YS; Wang YC; Lin JC
J Microbiol Immunol Infect; 2012 Jun; 45(3):214-20. PubMed ID: 22571999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
